Idursulfase, Human iduronate-2-sulfatase(IDS)

Specification

• Cat#: THP-0178
• Product Name: Idursulfase, Human iduronate-2-sulfatase(IDS)
• Cas No: 50936-59-9
• Description: The product is a purified form of human iduronate-2-sulfatase(IDS), a lysosomal enzyme, expressed in a human cell line. The product is an enzyme that hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans dermatan sulfate and heparan sulfate in the lysosomes of various cell types. The product is a 525-amino acid glycoprotein with a molecular weight of approximately 76 KDa. The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures. The enzyme activity of the product is dependent on the post-translational modification of a specific cysteine to formylglycine.
• Sequences: SETQANSTTDALNVLLIIVDDLRPSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAVCAPSRVSFLTGRRPDTTRLYDFNSYWRVHAGNFSTIPQYFKENGYVTMSVGKVFHPGISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPDGELHANLLCPVDVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGYHKPHIPFRYPKEFQKLYPLENITLAPDPEVPDGLPPVAYNPWMDIRQREDVQALNISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLANSTIIAFTSDHGWALGEHGEWAKYSNFDVATHVPLIFYVPGRTASLPEAGEKLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAGLAGLQVPPRCPVPSFHVELCREGKNLLKHFRFRDLEEDPYLPGNPRELIAYSQYPRPSDIPQWNSDKPSLKDIKIMGYSIRTIDYRYTVWVGFNPDEFLANFSDIHAGELYFVDSDPLQDHNMYNDSQGGDLFQLLMP
• Species: Human
• Molecular Weight: 76000.0 Da
• Source: Human Cells
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C2654H4000N688O774S14
• Endotoxin: <0.001 EU per 1 μg of the peptide by the LAL method
• Application: For the treatment of Hunter syndrome in adults and children ages 5 and older.
• Concentration: 2mg/ml
• Publication: iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II (Hong, J., Cheng, Y., Yang, S.,et al.) (Experimental Cell Research) (2022).
  Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome) (Gusarova, V.D., Smolov, M.A., Lyagoskin, I.V. et al.) (BioDrugs) (2023).
  

Pharmaceutical Information

• Pharmaceutical Application: Idursulfase
• Targets: Target 1. Dermatan sulfate; Target 2. Heparan sulfate; Target 3. Perilipin-3